Related Experiment Video
Updated: May 16, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Neoadjuvant chemotherapy for invasive bladder cancer: an interesting case report
Davide Abed El Rahman1, Victor Deliu Matei, Gennaro Musi
1Department of Urology, European Institute of Oncology IEO - Università degli Studi di Milano, Milano, Italy. davide.adel@libero.it
Abstract:
We report the case of a 66 years old woman with histological diagnosis of muscle-invasive high grade transitional cell carcinoma and clinical diagnosis (TC) of metastatic disease treated with a platinum based combination chemotherapy obtaining a pathologic complete response. Neoadjuvant chemotherapy for bladder cancer even with its limitations regarding patients selection, current development of surgical technique and current chemotherapy combination has shown to improve overall survival by 5-7% at 5 years and should be considered in muscle invasive bladder cancer, irrespective of definitive treatment.

